Zolidronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fractures: a meta-analysis of bone density improvement, recurrent vertebral fractures prevention, and long-term efficacy evaluation

doi:10.3969/j.issn.2095-4344.2721

Abstract

Abstract:

BACKGROUND: The clinical application of zoledronic acid in the treatment of osteoporosis lacks systematic scientific evaluation and evidence-based basis. Therefore, the clinical efficacy of zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic vertebral compression fracture is still uncertain.

OBJECTIVE: To systematically evaluate the efficacy of zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic vertebral compression fracture.

METHODS: A computer search of all randomized controlled studies and clinical trials of zolidronic acid combined with percutaneous kyphoplasty for the treatment of osteoporotic vertebral compression fracture published in CNKI, Wanfang, VIP, CBM, PubMed and Cochrane prior to September 2019 was performed. The experimental group was treated with zoledronic acid and percutaneous kyphoplasty, while the control group was treated with percutaneous kyphoplasty. Literature screening and data extraction were conducted by the two researchers independently. The quality of the included randomized controlled trials was evaluated one by one according to the Cochrane collaboration standards. Meta-analysis was performed on RevMan 5.3 for those that met the inclusion criteria.

RESULTS AND CONCLUSION: (1) Five randomized controlled trials were included, including 175 in the experimental group and 184 in the control group. (2) Meta-analysis results showed that the bone mineral density was higher in the experimental group than in the control group [MD=0.12, 95%CI(0.08, 0.17), P < 0.000 01]. The visual analogue scale score was lower in the experimental group than that of the control group 6 and 12 months after treatment [MD=0.46, 95%CI(0.18, 0.75), P=0.002; MD=0.85, 95%CI(0.20, 1.50), P=0.01]. At 1 year after treatment, Oswestry disability index was lower in the experimental group than in the control group [MD=6.59, 95%CI(4.77，8.41), P < 0.000 01]. Bone cement leakage rate and recurrence rate of vertebral fractures were lower in the experimental group than in the control group [OR=0.22, 95%CI(0.08, 0.59), P=0.003; OR=0.18, 95%CI(0.07, 0.50), P=0.000 8]. Vertebral height recovery and kyphotic Cobb angle were not significantly different between the two groups [MD=0.65, 95%CI(-0.27, 1.56), P=0.16; MD=-0.60, 95%CI(-2.45, 1.25), P=0.53]. (3) Results showed that compared with percutaneous kyphoplasty alone, zoledronic acid combined with percutaneous kyphoplasty has significant advantages in improving bone mineral density, reducing the recurrence rate of vertebral fracture, improving the long-term clinical symptoms of patients, preventing the bone cement leakage, but a large number of high-quality multi-center randomized controlled studies are still needed to provide more sufficient evidence in the later stage.

Key words: zoledronic acid, osteoporotic vertebral compression fracture, osteoporotic compression fracture, percutaneous kyphoplasty, bone mineral density, Cobb angle, system evaluation, effectiveness, safety, meta-analysis

CLC Number:

Li Kaiming, Zhu Liguo, Zhang Qing, Li Linghui, Xie Rui, Chen Ming, Liang Long, Lin Chengyu, Hou Xiaozhou. Zolidronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fractures: a meta-analysis of bone density improvement, recurrent vertebral fractures prevention, and long-term efficacy evaluation[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(24): 3911-3917.

Figures/Tables 12

References

[1] GAMBACCIANI M, LEVANCINI M. Management of postmenopausal osteoporosis and the prevention of fractures .Panminerva Med. 2014;56(2):115-131.
[2] LEMS WF, DEN HEIJER M. Established and forthcoming drugs for the treatment of osteoporosis.Neth J Med.2013;71(4):188-193.
[3] 皮海菊,肖淼生,尚晖.经皮椎体后凸成形术治疗陈旧性骨质疏松椎体压缩性骨折疗效观察[J].中国临床研究,2017,30(1):27-30.
[4] GOLDSTEIN CL, CHUTKAN NB, CHOMA TJ, et al. Management of the elderly with vertebral compression fractures. Neurosurgery. 2015;77(4):S33-45.
[5] GAINES JM, MARX KA. Older men,s knowledge about osteoporosis and educational intervenetions to increase osteoporosis knowledge in older men: a systematic review.Maturitas.2011;68(1):5-12.
[6] 刘新奇,叶福生,王永光,等.唑来膦酸治疗老年患者经皮椎体后凸成形术后椎体再骨折的短期疗效[J].中华骨质疏松和骨矿盐疾病杂志, 2015,8(1):4852
[7] 刘明明,程建,黄桂成,等.唑来膦酸与PKP治疗骨质疏松性椎体压缩骨折[J].中国矫形外科杂志,2015,23(22):2017-2020.
[8] 玄文虎,欧阳剑锋,王素伟.小剂量骨水泥椎体后凸成形联合唑来膦酸治疗骨质疏松椎体压缩性骨折[J].中国组织工程研究,2017,21(26): 4101-4105.
[9] SHI C, ZHANG M, CHENG AY, et al. Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly.Clin Interv Aging. 2018;13:853-861.
[10] HUANG ZF, XIAO SX, LIU K, et al. Effectiveness Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in Treatment of Primary Osteoporotic Vertebral Compression Fractures. Pain Physician.2019;22(1):63-68.
[11] LIU B,GAN F,GE Y, et al.Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures.J Invest Surg. 2018;31(5):425-430.
[12] KOIVISTO K, KYLLONEN E, HAAPEA M, et al. Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging.BMC Musculoskelet Disord. 2014;4(15):64.
[13] 娄玉健,王秀会,陆耀刚.骨质疏松性椎体压缩骨折椎体后凸成形术与非手术治疗的临床对照研究[J].中国骨与关节损伤杂志,2014,17(1): 15-17.
[14] NAKANO M, HIRANO N, ZUKAWA M, et al. Vertebroplasty using calcium phosphate cement for osteoporotic vertebral fractures: study of outcomes at a minimum follow-up of two years.Asian Spine J. 2012;6(1):34 -42.
[15] YIN F, SUN Z, SONG S, et al. A comparative study on treatment of mid-thoracic osteoporotic vertebral compression fracture using percutaneous kyphoplasty with unilateral and bilateral approaches. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2016;30(1):77-81.
[16] KANATLI U, ATAOGLU B, OZER M, et al. Kyphoplasty for intractable pain due to glucocorticosteroid-induced osteoporotic vertebra fracture of a 9-year-old patient with systemic lupus erythematosus: 8-year follow-up.J Pediatr Orthop.2015;35(6): e55-59.
[17] 苏其昌,张汉庆,王晓慧. 经皮球囊扩张椎体后凸成形术与保守治疗骨质疏松性椎体压缩性骨折的Meta分析[J].江汉大学学报,2018,46(1): 78-82.
[18] ZHENG ZM, LI FB.[Percutaneous vertebroplasty and kyphoplasty- problem and strategy].Zhonghua Yi Xue Za Zhi. 2006;86(27): 1878-1880.
[19] LUO J, ANNESLEY-WILLIAMS DJ, ADAMS MA, et al. How are adjacent apinal levels affected by vertebral fracture and by vertebaoplasty?A biomechanical study on cadaveric spines.Spine J.2017;17(6):863-974.
[20] RHO YJ, CHOE WJ, CHUN YI. Risk factors predicting the new symptomatic vertebral compression fractures after percutaneous vertebroplasty or kyphoplasty.Eur Spine J.2012;21(5):905-911.
[21] NOURINIA R, AHMADIEH H, REZAEI-KANAVI M, et al. Safety of Intravitreal Zoledronic Acid,an Anti-Angiogenic Bisphosphonate,in a Rat Model.J Ophthalmic Vis Res.2014;9(1):44-49.
[22] ZHANG ZL, LIAO EY, XIA WB, et al. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int.2015;26(9):2365-2374.
[23] KIM BS, YANG SS, KIM CS, et al. Zoledronate suppresses VEGF‑induced capillary tube formation and inhibits expression of interferon‑induced transmembrane protein-1 in human umbilical vein endothelial cells.Int J Mol Med.2018;41(5):2879-2884.
[24] SAFER U,SAFER VB,DEMIR SO,et al.Effects of bisphosphonates and calcium plus vitamin-D supplements on cognitive function in postmenopausal osteoporosis section sign.Endocr Metab Immune Disord Drug Targets.2016;16(1):56-60.
[25] 史占广.唑来膦酸对骨质疏松性压缩骨折患者经皮椎体成形术术后骨密度及临床症状的影响[J].中国药物经济学,2019,14(9):81-83.
[26] BELL KJ, HAYEN A, GLASZIOU P, et al.Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis:Secondary Analysis of Randomized Controlled Trial Data.Bone Miner Res.2016;31(9): 1767-1773.
[27] SPIEGEL R, NAWROTH PP, KASPERK C. The effect of zoledronic acid on the fracture risk in men with osteoporosis.J Endocrinol Invest.2014;37(3):229-232.
[28] 苏祥正,毛克亚,刘郑生,等.椎体成形术后骨水泥渗漏分析[J].解放军医学院学报,2014,35(10):987-989.
[29] HUANG S, LIN H, ZHU X, et al. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.Endokrynol Pol.2014;65(2):96-104.
[30] 梁文清,钱宇,郦仕杰,等.唑来膦酸对骨质疏松性椎体压缩骨折PKP术后疗效的影响[J].中国骨与关节损伤杂志, 2015,30(9):926-929.
[31] DING Q, CHEN J, FAN J, et al. Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. Eur Spine J.2017;26(11): 2969-2977.